Study Identifies Brain Circuit Responsible for Placebo Pain Relief in Mice
Researchers using a mouse model of neuropathic pain have identified a specific neural circuit in the anterior cingulate cortex (ACC) responsible for placebo analgesia. The study combined whole-brain activity mapping with targeted circuit manipulations to show that mu-opioid receptor-expressing neurons in the ACC are necessary for placebo pain relief. The findings offer a concrete molecular and anatomical target for understanding — and potentially enhancing — placebo responses in chronic pain conditions.
A new preprint study published on bioRxiv established a conditioning-based placebo analgesia paradigm in mice with peripheral nerve injury, using morphine conditioning to produce drug-free reductions in pain sensitivity. Whole-brain c-Fos expression mapping revealed widespread changes across cortical and subcortical regions, along with a reorganization of functional connectivity suggesting coordinated network-level engagement during placebo analgesia. Network analyses identified shifts in hub structure and selective strengthening or weakening of connections between brain regions. Causal circuit manipulations showed that activating the anterior cingulate cortex (ACC) blocked placebo analgesia, while inhibiting it had no effect; other candidate regions such as the basomedial amygdala and paraventricular thalamus were not required. Critically, selectively targeting mu-opioid receptor-expressing neurons in the ACC demonstrated that this specific cell population is necessary for placebo analgesia to occur. The results point to a cortical opioid circuit that acts as a gating mechanism for placebo pain relief, with potential implications for treating neuropathic pain.
What's missing
As a preprint, this study has not yet undergone formal peer review. The paradigm relies on morphine conditioning in mice, leaving open whether similar ACC mu-opioid mechanisms underlie placebo analgesia in humans or in pain models not involving prior opioid exposure. The study does not address whether the identified circuit could be therapeutically modulated without risk of opioid-related side effects.
What different sources said
- bioRxivCenter
Whole-brain analyses identify anterior cingulate μ-opioid signaling as a critical mediator of placebo analgesia in neuropathic pain
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.